Impact of short and long exposure to cafeteria diet on food intake and white adipose tissue lipolysis mediated by glucagon-like peptide 1 receptor - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37293487/
Exposure to a CAF diet during the early stages of obesity reduces the effects of peripheral and central GLP1R agonists, and WAT does not express a functional GLP1 receptor. These...
Discussion: Exposure to a CAF diet during the early stages of obesity reduces the effects of peripheral and central GLP1R agonists, and WAT does not express a functional GLP1 receptor. These data support that exposure to the obesogenic food environment, without the development or manifestation of obesity, can alter the response to GLP1R...
Share
Perspectives on weight control in diabetes - Tirzepatide - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37279858/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions/Relevance: These findings suggest that the robust weight loss and associated changes are important contributors to the clinical profile of tirzepatide for the treatment of T2D diabetes and serve as the basis for further investigations including clinical outcomes.
Share
Conclusions: The combination of aerobic training and semaglutide treatment synergistically improved β-cell secretory function.
Share
Relevance: Novo Nordisk, the drug’s developer, announced the study’s topline results in a press release. On average, participants experienced a 15.1% decrease in weight after receiving the medication, regardless of treatment adherence, compared with a 2.4% weight loss with the placebo. The amount of weight loss with oral semaglutide was...
Share
Clinical outcomes associated with drugs for obesity and overweight: A systematic review and network meta-analysis of randomized controlled trials - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37254688/
Among adults with obesity or overweight, semaglutide and phentermine/topiramate were associated with greater body weight loss and waist circumference reduction at 12 months than all other drugs, and lower or...
Conclusions: Among adults with obesity or overweight, semaglutide and phentermine/topiramate were associated with greater body weight loss and waist circumference reduction at 12 months than all other drugs, and lower or no significant difference in risks of withdrawal. There was no evidence that drugs approved for weight management had...
Share